Viatris Inc. VTRS
20.74 USD -0.08 (-0.38%)
Regular-session close
20.58 -0.16 -0.79%
Pre-market · Nov 17, 4:20 AM ET
20.61 Day range 20.98
10.15 52-week range 21.20
- YTD
- +66.59%
- 1 year
- +93.47%
News
benzinga.com Barclays Maintains Overweight on Viatris, Raises Price Target to $25 Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $22 to $25.
prnewswire.com Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year PITTSBURGH, Nov. 12, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for the second…
prnewswire.com Viatris to Participate in Upcoming Investor Conferences PITTSBURGH, Nov. 11, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare…
zacks.com VTRS or DHR: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
zacks.com Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue? Viatris (VTRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
benzinga.com Viatris Q3 2026 Earnings Call Transcript Viatris (NASDAQ:VTRS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Viatris Raises FY2026 Adj EPS Guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 Est; Narrows FY2026 Sales Guidance from $14.550B-$14.950B to $14.700B-$14.900B vs $14.788B Est Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 analyst estimate. Narrows FY2026 sales outlook from $14.550 billion-$14.950 billion to $14.700…
benzinga.com Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
benzinga.com Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14 Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $13 to $14.
benzinga.com JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20 JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $18 to $20.
finance.yahoo.com SK hynix Inc. (SKHY) SK hynix posted exceptional third-quarter results, supported by artificial-intelligence memory demand, long-term customer contracts, and strong profitability. Recent selling reflects concerns about…
finance.sina.com.cn VTRS收跌0.38%,成交额1.48亿美元 该公司销售品牌药和仿制药,包括复杂药物。该公司的分部包括发达市场、大中华区、JANZ以及新兴市场。发达市场分部主要包括北美和欧洲业务。大中华区分部包括中国大陆、台湾和中国香港业务。JANZ分部包括日本、澳大利亚和新西兰业务。新兴市场分部覆盖125多个国家的发展中市场和新兴经济体,包括亚洲、非洲、东欧、拉丁美洲和中东,以及该公司的抗逆转录病毒(ARV)业务。该公司在多个主要治疗领域提供药品,从心血管…
finance.sina.com.cn LYLD前十大重仓股占比22.2511%,第一大重仓股为Maplebear Inc. ORD 数据显示,LYLD前十大重仓股合计占基金资产的22.2511%。 其中,第一大重仓股为Maplebear Inc. ORD,持仓占比2.4492%;第二大重仓股为美元树,占比2.3229%;第三大重仓股为美国史丹利公司,占比2.3024%。 此外,前十大重仓股还包括伊克力西斯、Fortive Corporation、VTRS、杜邦、康卡斯特、美国金融集团有限公司和BALL。…
finance.yahoo.com Larry Robbins's Top Q3 2026 Move: CVS Health Corp at a -6.68% Portfolio Impact At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
markets.ft.com CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER The Cadillac Formula 1® Team and Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced a multiyear partnership that makes Viatris the team's Official Global Pharmaceutical Partner…
tipranks.com DME Capital buys SL Green, exits PayPal in Q3 David Einhorn’s DME Capital Management disclosed in an SEC filing its holdings as of September 30, 2026. The fund’s new buys during the third quarter included by ...
msn.com Einhorn's DME exits PayPal, Stubhub, adds Century Aluminum, among Q3 moves David Einhorn's DME Capital Management added stakes in Century Aluminum (CENX), SL Green (SLG), and MGM Resorts (MGM) and exited stakes in PayPal (PYPL) and StubHub (STUB), according to its latest…
marketscreener.com Cadillac Formula 1 Team Announces Multiyear Partnership With Viatris Inc. As Official Global Pharmaceutical Partner Cadillac Formula 1 Team and Viatris Inc. announced a multiyear partnership that makes Viatris the team's Official Global ...
